BACKGROUND AND AIMS: Macrophages play an important role during mucosal inflammation in inflammatory bowel disease (IBD). As the co-stimulatory molecules B7-1 (CD80) and B7-2 (CD86) play an integral role in the activation of T cells by antigen-presenting cells (APC) we investigated the surface expression of B7-1 and B7-2 on colonic macrophages from normal and IBD mucosa. METHODS: Intestinal macrophages were isolated from biopsies of 13 control persons and 14 patients with IBD (seven with Crohn's disease (CD); and seven with ulcerative colitis (UC)). Cells were characterized by triple fluorescence flow cytometrical analysis using CD33 as macrophage marker. RESULTS: The expression of B7-1 (CD80) (9.2% +/- 4.2%) and B7-2 (CD86) (15.1% +/- 7.3%) was low on colonic macrophages from normal mucosa, indicating only a low antigen presenting potential. However, on macrophages from IBD colon there was a significant increase in the expression of co-stimulatory molecules (CD80, 33.8% +/- 8.9%, P = 0.00005 vs. control; CD86, 39.9% +/- 8.8%, P = 0.00002). There was no significant difference between CD and UC in the expression of CD80 (CD, 31.3% +/- 6.7%; UC, 34.4% +/- 13.3%) and CD86 (CD, 41.9% +/- 3.8%; UC, 35.6% +/- 13.8%). While in normal mucosa only 10.6% +/- 4.9% of the macrophages expressed CD14, more than 90% of the CD86/CD80 positive cells of the inflamed mucosa were positive for CD14. CONCLUSION: Colonic macrophages from normal mucosa rarely express the co-stimulatory molecules CD80 and CD86. In IBD a new macrophage population is found with high expression of co-stimulatory molecules presumably responsible for the perpetuated immune response.
BACKGROUND AND AIMS: Macrophages play an important role during mucosal inflammation in inflammatory bowel disease (IBD). As the co-stimulatory molecules B7-1 (CD80) and B7-2 (CD86) play an integral role in the activation of T cells by antigen-presenting cells (APC) we investigated the surface expression of B7-1 and B7-2 on colonic macrophages from normal and IBD mucosa. METHODS: Intestinal macrophages were isolated from biopsies of 13 control persons and 14 patients with IBD (seven with Crohn's disease (CD); and seven with ulcerative colitis (UC)). Cells were characterized by triple fluorescence flow cytometrical analysis using CD33 as macrophage marker. RESULTS: The expression of B7-1 (CD80) (9.2% +/- 4.2%) and B7-2 (CD86) (15.1% +/- 7.3%) was low on colonic macrophages from normal mucosa, indicating only a low antigen presenting potential. However, on macrophages from IBD colon there was a significant increase in the expression of co-stimulatory molecules (CD80, 33.8% +/- 8.9%, P = 0.00005 vs. control; CD86, 39.9% +/- 8.8%, P = 0.00002). There was no significant difference between CD and UC in the expression of CD80 (CD, 31.3% +/- 6.7%; UC, 34.4% +/- 13.3%) and CD86 (CD, 41.9% +/- 3.8%; UC, 35.6% +/- 13.8%). While in normal mucosa only 10.6% +/- 4.9% of the macrophages expressed CD14, more than 90% of the CD86/CD80 positive cells of the inflamed mucosa were positive for CD14. CONCLUSION: Colonic macrophages from normal mucosa rarely express the co-stimulatory molecules CD80 and CD86. In IBD a new macrophage population is found with high expression of co-stimulatory molecules presumably responsible for the perpetuated immune response.
Authors: J Schröder-Braunstein; V Pavlov; T Giese; A Heidtmann; S Wentrup; F Lasitschka; J Winter; A Ulrich; A Engelke; M Al Saeedi; S Meuer Journal: Clin Exp Immunol Date: 2012-04 Impact factor: 4.330
Authors: M Hausmann; T Spöttl; T Andus; G Rothe; W Falk; J Schölmerich; H Herfarth; G Rogler Journal: Clin Exp Immunol Date: 2001-07 Impact factor: 4.330
Authors: K Schreiter; M Hausmann; T Spoettl; U G Strauch; F Bataille; J Schoelmerich; H Herfarth; W Falk; G Rogler Journal: Gut Date: 2005-07 Impact factor: 23.059
Authors: Susanne A Snoek; Marleen I Verstege; Esmerij P van der Zanden; Nigel Deeks; David C Bulmer; Michael Skynner; Kevin Lee; Anje A Te Velde; Guy E Boeckxstaens; Wouter J de Jonge Journal: Br J Pharmacol Date: 2010-05 Impact factor: 8.739
Authors: K Menzel; M Hausmann; F Obermeier; K Schreiter; N Dunger; F Bataille; W Falk; J Scholmerich; H Herfarth; G Rogler Journal: Clin Exp Immunol Date: 2006-10 Impact factor: 4.330
Authors: J Braunstein; F Autschbach; T Giese; F Lasitschka; A Heidtmann; B Sido; B Funke; C Reiser; A J Schröder; G Nebl; Y Samstag; S C Meuer Journal: Clin Exp Immunol Date: 2008-03 Impact factor: 4.330
Authors: M Hausmann; F Obermeier; K Schreiter; T Spottl; W Falk; J Schölmerich; H Herfarth; P Saftig; G Rogler Journal: Clin Exp Immunol Date: 2004-04 Impact factor: 4.330